Collegium Pharmaceutical (COLL) News Today → Does this make you sick? (From Allegiance Gold) (Ad) Free COLL Stock Alerts $34.15 +1.68 (+5.17%) (As of 04:16 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 5:40 AM | americanbankingnews.comGaren G. Bohlin Sells 28,985 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) StockMay 17 at 12:08 PM | insidertrades.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Director Garen G. Bohlin Sells 28,985 SharesMay 17 at 6:59 AM | marketbeat.comJump Financial LLC Buys New Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Jump Financial LLC acquired a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 38,300 shares of the specialty pharmaceutical company's stock, vMay 14, 2024 | insidermonkey.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2024 Earnings Call TranscriptMay 14, 2024 | marketbeat.comNational Bank of Canada FI Buys New Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)National Bank of Canada FI purchased a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 59,400 shares of the sMay 13, 2024 | markets.businessinsider.comCollegium Pharmaceutical Enters ASR Agreement To Repurchase $35 Mln Of Common StockMay 13, 2024 | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up to $31.50Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up to $31.50May 13, 2024 | seekingalpha.comCollegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'May 13, 2024 | globenewswire.comCollegium Announces $35 Million Accelerated Share Repurchase ProgramMay 13, 2024 | americanbankingnews.comPiper Sandler Lowers Collegium Pharmaceutical (NASDAQ:COLL) to NeutralMay 13, 2024 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Cut to "Hold" at Needham & Company LLCMay 12, 2024 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down to $37.86May 11, 2024 | uk.finance.yahoo.comCollegium Pharmaceutical Reports First Quarter 2024 EarningsMay 11, 2024 | uk.finance.yahoo.comCollegium Pharmaceutical Reports First Quarter 2024 EarningsMay 11, 2024 | msn.comCollegium downgraded by Piper Sandler over valuationMay 11, 2024 | msn.comNeedham Downgrades Collegium Pharmaceutical (COLL)May 10, 2024 | finanznachrichten.deCollegium Pharmaceutical, Inc.: Collegium Reports First Quarter 2024 Financial ResultsMay 10, 2024 | markets.businessinsider.comDemystifying Collegium Pharmaceutical: Insights From 4 Analyst ReviewsMay 10, 2024 | finance.yahoo.comCollegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Looks Like They Deserve Their Pay PacketMay 10, 2024 | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Downgraded to Hold at Needham & Company LLCNeedham & Company LLC cut Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a report on Friday.May 10, 2024 | msn.comCOLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | msn.comCollegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 9, 2024 | finance.yahoo.comCollegium Announces CEO TransitionMay 9, 2024 | marketwatch.comCollegium Pharmaceutical CEO Joe Ciaffoni Steps DownMay 9, 2024 | globenewswire.comCollegium Reports First Quarter 2024 Financial ResultsMay 9, 2024 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Holdings Raised by LSV Asset ManagementLSV Asset Management increased its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 75.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 131,800 shares of the specialty pharmaceuticMay 8, 2024 | finance.yahoo.comWarner Bros. Discover earnings, Fedspeak: What to watchMay 8, 2024 | markets.businessinsider.comCollegium Pharmaceutical earnings: here's what Wall Street expectsMay 7, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Rocket Pharmaceuticals (RCKT)May 4, 2024 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by New York State Common Retirement FundNew York State Common Retirement Fund grew its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 1,475.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 201,112 sharMay 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Jazz Pharmaceuticals (JAZZ) and KalVista Pharmaceuticals (KALV)May 1, 2024 | stocknews.com3 Popular Pharma Stocks Worth Buying NowMay 1, 2024 | finance.yahoo.comAvalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business OfficerApril 30, 2024 | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Trading Up 3.8%Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Up 3.8%April 29, 2024 | msn.comCollegium enters authorized generic agreement with Hikma for Nucynta franchiseApril 29, 2024 | finance.yahoo.comCollegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ERApril 26, 2024 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Acquired by Federated Hermes Inc.Federated Hermes Inc. increased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 76.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 212,768 shares of the specialty pharmaceApril 25, 2024 | globenewswire.comCollegium to Report First Quarter 2024 Financial Results on May 9, 2024April 23, 2024 | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Upgraded to "Strong-Buy" by StockNews.comStockNews.com raised Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Tuesday.April 23, 2024 | money.usnews.comCollegium Pharmaceutical IncApril 12, 2024 | markets.businessinsider.comOptimistic Buy Rating for Collegium Pharmaceutical: Growth and Market Position AnalysisApril 11, 2024 | markets.businessinsider.comCritical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To KnowApril 11, 2024 | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Trading Down 3.9%Collegium Pharmaceutical (NASDAQ:COLL) Shares Down 3.9%April 11, 2024 | marketbeat.comCollegium Pharmaceutical's (COLL) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $40.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday.April 11, 2024 | globenewswire.comCollegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026April 9, 2024 | finance.yahoo.comCollegium Pharmaceutical (COLL) Stock Sinks As Market Gains: What You Should KnowApril 9, 2024 | marketbeat.comPeregrine Capital Management LLC Decreases Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Peregrine Capital Management LLC reduced its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 25.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 344,532 shares of the specialApril 4, 2024 | bizjournals.comNovan is gone. But its lead drug lives on with new companyApril 3, 2024 | markets.businessinsider.comLigand Pharmaceuticals Announces Launch Of Pelthos; Scott Plesha To Assume Leadership Of PelthosApril 3, 2024 | finance.yahoo.comCollegium to Participate in 23rd Annual Needham Virtual Healthcare Conference Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address Everybody laughed when he recommended Netflix (Ad)"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. COLL Media Mentions By Week COLL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COLL News Sentiment▼0.490.42▲Average Medical News Sentiment COLL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COLL Articles This Week▼73▲COLL Articles Average Week Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VRNA News Today PRTA News Today ELVN News Today ABCL News Today IRWD News Today INVA News Today MIRM News Today SAVA News Today TYRA News Today BCYC News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COLL) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDoes this make you sick?Allegiance GoldThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
